← Back to Search

Local Anesthetic

Drug: Bupivacaine 0.375% 20 mL for Acute Pain

Phase 4
Waitlist Available
Led By Anna Uskova, MD
Research Sponsored by Anna Uskova
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients 18-80 years old Patients undergoing total hip arthroplasty BMI 19-45, >50 kg Male and Female All races American Society of Anesthesiologists physical status classification I, II, III Spinal Anesthesia Provided
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights

Study Summary

This trial looks at whether the amount of local anesthetic injected during a quadratus lumborum block is more important than the concentration of the anesthetic in terms of pain control and opioid consumption after surgery.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
consumption of opioids during the first 24 hours after surgery.
Secondary outcome measures
Analgesics, Non-Narcotic
Pain measurement through VAS (Visual Analogue Score) at rest and with movement
Patient satisfaction 24 hours after surgery.
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: High Volume groupExperimental Treatment1 Intervention
30 subjects randomized to High Volume will receive unilateral Quadratus lumborum block Type II. Each block of 0.375% Bupivacaine x 20 mL + Normal Saline Solution 20 mL
Group II: Low Volume groupActive Control1 Intervention
30 subjects randomized to Low Volume will receive unilateral Quadratus Lumborum block type II. Each block of 0.375% Bupivacaine x 20 ml
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Drug: Bupivacaine 0.375% 20 mL
2021
Completed Phase 4
~60

Find a Location

Who is running the clinical trial?

Anna UskovaLead Sponsor
1 Previous Clinical Trials
University of PittsburghLead Sponsor
1,712 Previous Clinical Trials
16,346,351 Total Patients Enrolled
7 Trials studying Acute Pain
23,791 Patients Enrolled for Acute Pain
Anna Uskova, MDPrincipal Investigator - University of Pittsburgh
UPMC Presbyterian, UPMC Shadyside
Kazan State Medical Inst (Medical School)
University Hlth Ctr Of Pittsburgh (Residency)
2 Previous Clinical Trials
45 Total Patients Enrolled
1 Trials studying Acute Pain
45 Patients Enrolled for Acute Pain

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor presently open to participants?

"This medical study has been accepting participants since April 1st 2021, according to the records hosted on clinicaltrials.gov. The trial was last modified on March 29th 2022."

Answered by AI

Has the FDA sanctioned Bupivacaine 0.375% 20 mL for clinical use?

"Our team's assessment of the safety of Drug: Bupivacaine 0.375% 20 mL was a 3, due to its Phase 4 status and subsequent authorization for use by regulatory bodies."

Answered by AI

Is the eligibility criterion of this experiment limited to those under 40 years old?

"For this research, individuals aged 18 and above but below the age of 90 are eligible for enrollment."

Answered by AI

To what maladies is the medication Bupivacaine 0.375% 20 mL typically administered?

"Drug: Bupivacaine 0.375% 20 mL can be implemented to treat permphigus, acute nonspecific tenosynovitis, and general anesthesia."

Answered by AI

What findings have been reported from previous investigations utilizing Bupivacaine 0.375% 20 mL?

"Currently, 18 Phase 3 trials of Drug: Bupivacaine 0.375% 20 mL are active with a total of 109 studies being conducted. Although there are numerous Philadelphia locations where this drug is tested, the scope extends to 144 sites throughout the country."

Answered by AI

Is there a way for me to participate in this trial?

"This trial seeks to enroll 60 patients between ages 18 and 90 with acute pain. In order to qualify, they must be aged between 18-80 years old, have a body mass index (BMI) of 19-45 or larger than 50 kgs, identify as male or female regardless of race, possess an American Society of Anesthesiologists physical status classification I-III and receive spinal anesthesia."

Answered by AI

What is the aggregate sum of individuals taking part in this investigation?

"Affirmative. Data hosted on clinicaltrials.gov verifies this medical trial is actively seeking out participants; the initial posting was made April 1st 2021 and a subsequent update occurred March 29th 2022. Two sites are looking to enroll 60 individuals in total between them."

Answered by AI
~15 spots leftby Mar 2025